The reiteration of a Buy rating and maintenance of a $6.5 price target by a reputable analyst like Arthur He from HC Wainwright & Co. is likely to instill confidence among investors and could positively influence HOOKIPA Pharma's stock price in the short term. The specific mention of the company and the reaffirmation of the price target suggest a strong belief in the company's potential.